Back to search

University of Patras

Παρασκευή, μελέτη σταθερότητας και αποτελεσματικότητας (in vitro και in vivo) νανολιποσωμάτων για χορήγηση φαρμάκων στον εγκέφαλο

Abstract

dc:description

Drug development for the Central Nervous System is seriously hampered by the lack of effective methods for permeation of drugs through the BBB and into the brain. For this reason, research is directed to the use of nanoparticles for the penetration of BBB. The use of targeted nanoparticles is recently upgraded and researchers attempt to resolve the configuration issues and transport across the BBB to develop commercially available products. Various types of nanoparticles are under investigation for transporting drugs across the BBB, whereas studies of such nanoparticles aided the development of cell model of BBB. In this study we used hCMEC/D3 cell line as an in vitro model of BBB to investigate the influence of size and surface charge of nanosized liposomes in their interaction with these cells and to eliminate the possibility of misinterpretation of targeting capacity of larger decorated liposomes during in vitro tests. Liposomes with different average diameters, ideally between 50 and 400nm and a different negative z-potential were evaluated, for their uptake by hCMEC/D3 cells and for their permeability across monolayers of hCMEC/D3 cells. Results showed that the size of liposomes have a significant effect both on the uptake by cells and in their permeability across cell monolayers. This has been verified for uncharged liposomes composed of DSPC and for liposomes with a negative surface charge (which has been replaced 10mole% [the total lipid mole] with DSPG). On the other hand, the effect liposome surface charge in their interaction with the hCMEC/D3 cells were less pronounced (in the range of different surface charge values were evaluated from -2 to -16mV). The replacement of part of DSPC with DSPG, at such a low amount as 5mol% (of total lipid), causes a significant increase in uptake of liposomes by the cells. However any further increase in the uptake of the liposomes was observed when used even higher concentrations of DSPG (up to 15mol%). Moreover, increasing the negative charge of the liposome surface does not significantly affect their transport across the monolayer in the range between -2 and -12.9mV, but it was observed a significant reduction in permeability across cell monolayers in liposomes with larger negative value zeta-potential (-16mV) among those tested. Moreover, permeability valuew of various liposomal formulations across the cell monolayer was calculated, which confirmed the effect of liposome size and charge in the transfer rate from the monolayer.Then, in order to develop targeted liposomes to release imaging agents and/or therapeutic agents against Alzheimer's disease and other related diseases of the CNS, targeted liposomes and dual targeted liposomes were prepared using a monoclonal antibody (OX-26) for the transferrin receptor (known for targeting of the transferrin receptor), and a peptide derivative of apolipoprotein E3 (ApoE) targeting the receptor associated with low density lipoprotein (LPR), for the first time together in the same liposome. To investigate whether the dual-targeted liposomes have enhanced targeting ability of BBB compared to corresponding targeted liposomes in vitro and in vivo studies were performed, in which the targeting ability of the different types of liposomes is compared to non-targeted PEG liposomes. After application of different ligand attachment methodologies in order to achieve optimal ligand immobilization yield and lipid recovery, targeted liposomes were evaluated for their BBB targeting ability to hCMEC/D3 cells and then in vivo, in order to investigate whether the in vitro model of BBB can predict the in vivo behavior of liposomes. After evaluating liposome characteristics (size distribution, z-potential, etc.) and if considered sufficient for in vivo administration, dual targeted liposomes were subjected to in vitro testing to investigate: (i) Their cytotoxicity potential and (ii) Their uptake by hCMEC/D3 cells and their ability to transport through the in vitro model of BBB. In all in vitro studies, results showed significant improvement of brain targeting ability for dual-targeted liposomes (higher cell uptake and higher permeability through the monolayers of hCMEC/D3) compared to liposomes without ligands (simple PEG- liposomes) or with liposomes having only one ligand, which showed satisfactory results (a higher uptake and penetration) compared with PEG-liposomes. Moreover, no liposome form caused no cytotoxicity. Two in vivo live imaging studies of mice (using DiR dye for liposome monitoring) confirmed the brain targeting capacity of dual targeted liposomes. However, additional in vitro studies were performed in which interactions of these liposomes with cells in the presence of increasing concentrations of serum proteins were evaluated, to investigate whether probably a better correlation between in vitro and in vivo results can be produced, in different experimental conditions.The same in vitro and in vivo studies were carried out for liposomes composed of different lipid mixtures, sphingomyelin with PA and decorated with ApoE peptide at different concentrations of ligand in the liposome surface (if considered sufficient in vivo administration) and has shown previously their ability to bind with high affinity to Aβ1-42 peptides. The cellular uptake of nanosized liposomes of sphingomyelin with 2.5mol% ApoE was increased compared with those with 0.05mol% in the presence of serum proteins in 5%, but with increasing concentration of serum proteins to the modified cell model, the cellular uptake of these is decreased in all cases (in the presence of PA and/or PEG), which is not observed in the liposomes of sphingomyelin with ApoE in 0.05mol% density, even in the presence of 50% of serum proteins. In the in vivo study of BBB targeting only sphingomyelin liposomes with 0.05mol% density of the peptide and without the presence of the PA was studied, because of their better behavior in the in vitro tests, having as control samples ApoE-liposomes composed of DSPC lipid. There was no increased targeting ability of BBB, which however probably depends on the ligands density at the surface and the lipid dose administered intravenously.Finally, multifunctional liposomes decorated with a curcumin lipid derivative which is referred as Treg (this derivative has been shown to exhibit very high affinity for Aβ peptides, when immobilized to liposomal surfaces), except to the two ligands for BBB targeting were prepared as a likely diagnosis/treatment system for Alzheimer's disease. Immobilization of ligands to liposome surface was optimized, by evaluating different methodologies and the chosen technique gave the best results in terms of the size of liposomes, the attachment yield of ligands and the lipid recovery. After having established that multifunctional liposomes have sufficient stability and integrity and showed no toxicity, then they tested for their BBB targeting ability (compared with dual-targeted liposomes). Results showed that multifunctional liposomes seem to have similar BBB targeting ability to that of dual targeted liposomes. In vivo studies confirmed the similar behavior of multifunctional liposomes and dual targeted liposomes with respect to their ability to reach the brain, in good correlation with the in vitro studies in the cellular BBB model. Multifunctional liposomes with simple BBB ligand density at their surface have slightly higher fractions of DiR signals to the brain/body compared to the corresponding double density. By increasing the density of BBB targeting ligands in multifunctional liposomes, their ability to target BBB and remain in the brain is reduced, which is likely due to some interactions between Treg and amyloid in the brain, or in the interaction between BBB targeting ligands and Treg molecules (which causes a reduced ability for BBB targeting ligands to interact with cellular receptors in BBB cells).

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papadia, Konstantina
  • Παπαδιά, Κωνσταντίνα

Subjects

dc:subject × 8

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38933

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papadia, Konstantina; Παπαδιά, Κωνσταντίνα. Παρασκευή, μελέτη σταθερότητας και αποτελεσματικότητας (in vitro και in vivo) νανολιποσωμάτων για χορήγηση φαρμάκων στον εγκέφαλο. University of Patras, 2016. http://hdl.handle.net/10442/hedi/38933